TAGRISSO 80 mg/1

TAGRISSO 80 mg is a medication used to treat certain types of lung cancer. This oral tablet contains osimertinib, a targeted therapy designed to inhibit specific cancer cell growth.

TAGRISSO 80 mg is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets cancer cells with EGFR mutations, helping to slow tumor growth. Patients often wonder, 'What is TAGRISSO used for?' This medication is typically prescribed for advanced or metastatic NSCLC, either as a first-line treatment or after other therapies have been tried.

Common effects of TAGRISSO 80 mg may include diarrhea, rash, and dry skin. Some users also report fatigue and changes in appetite. These effects can vary in severity and duration, and it's important to monitor any persistent or severe symptoms.

TAGRISSO 80 mg should be handled with care, following the prescribed dosage and administration guidelines. It is essential to inform healthcare providers about any pre-existing conditions or allergies. Pregnant women or those planning to become pregnant should discuss the risks and benefits with their healthcare provider.

TAGRISSO 80 mg may interact with certain medications, including those that affect liver enzymes. It is advisable to avoid grapefruit or grapefruit juice, as they can impact the effectiveness of the medication. Always consult a healthcare provider before starting or stopping any medication while taking TAGRISSO.